Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Gliadin peptide monoclonal antibody (14D5)

 
BPD-HYB-314-01-02 200 µg 388.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:alpha Gliadin
 
Clone:14D5
 
Host:Mouse
 
Isotype:IgG2aλ
 
Immunogen:Synthetic peptide corresponding to aa Lys57-Glu65-[α-gliadin (58-73)] (KLQPFPQPELPYPQPQ) of Gliadin-related peptide.
 
Species reactivity:Plant
 
Applications:ELISA, WB
 
Application Notes:Detects a band of ~6 to 10kDa by Western blot.
 
Purity Detail:Protein A/G-affinity purified.
 
Formulation:Liquid. In 0.01M phosphate buffer, pH 7.4, containing 0.5M sodium chloride and 15mM sodium azide.
 
Shipping:Blue Ice Not Frozen
 
Short Term Storage:+4°C
 
Scientific Background:Celiac disease is associated with a CD4+ T-cell response to epitopes of gliadin presented by HLA-DQ2 or -DQ8 class II MHC molecules. These epitopes are present in a 33-mer peptide of wheat alpha-gliadin, residues 56-88, which is resistant to digestion and forms a substrate for tissue transglutaminase (TG2), generating the glutamic acid residues essential for binding to HLA-DQ2. The immunogen corresponds to a deamidated form of a region that includes the T-cell epitopes, including the immunodominant PQPQLPY region and two PXPQP motifs associated with binding to IgA from patients with celiac disease. Complete homology exists between residues 63-73, 70-80 and 77-87 of wheat alpha gliadin.
 
BPD-HYB-314-01 WB
Figure 1. Gliadin peptide (detected with BPD-HYB 314-01) in rye (lane 1), barley (lane 2) and wheat (lane 3).
Please mouse over
BPD-HYB-314-01 WB

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Gliadin
By biological activity:
Gliadin Monoclonal antibody
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,